Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip?

As of Aug. 20, shares of Viking Therapeutics (NASDAQ: VKTX) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting to new clinical trial results regarding its oral obesity candidate, tentatively named VK2735.The good news was that oral VK2735 helped patients lose a lot of weight after just 13 weeks of daily dosing. Unfortunately, the candidate's safety profile didn't hold up. Poor tolerability among folks receiving the higher, more effective dosages was exactly the sort of problem that investors didn't want to see.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool